Regeneron Pharmaceuticals Inc. buy Citigroup Inc.
Start price
13.10.25
/
50%
€478.90
Target price
13.10.26
€568.00
Performance (%)
3.47%
Price
17.10.25
€495.50
Summary
This prediction is currently active. The BUY prediction by Citigroup_Inc_ shows slight gains of 3.47%. This prediction currently runs until 13.10.26. The prediction end date can be changed by Citigroup_Inc_ at any time. Citigroup_Inc_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Regeneron Pharmaceuticals Inc. | 3.47% |
| iShares Core DAX® | -1.072% |
| iShares Nasdaq 100 | 1.923% |
| iShares Nikkei 225® | 4.414% |
| iShares S&P 500 | 1.247% |
Comments by Citigroup_Inc_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Citigroup Inc. from $650.00 to $660.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
Stopped prediction by Citigroup_Inc_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€428.20
02.06.25
02.06.25
€571.68
02.06.26
02.06.26
15.92%
17.10.25
17.10.25
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€519.80
14.05.25
14.05.25
€625.59
14.05.26
14.05.26
-4.34%
17.10.25
17.10.25